Clinical Trial Update: A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating different doses of GSK's RSV vaccine (GSK3003891A) in healthy adult women to assess immune response and safety; study completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• GSK3003891A (GSK3003891A)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: COMPLETED | Results posted: 2018-11-20